Samsung Medical Center announced on the 25th that it won the grand award in the hospital category at the 'Mobile Award Korea 2025', sponsored by the Ministry of Science and ICT and the Korea Creative Content Agency, and organized by Digital Chosun Ilbo, for eight consecutive years. Samsung Medical Center's mobile non-face-to-face services surpassed 60 million annual views for the first time last year, with the number of annual users exceeding 7.8 million. Key services include pre-consultation screening, waiting status displays, medical institution identification verification through telecommunications company authentication, mobile registration and admission procedures, postpaid card registration, interim inpatient payments, and issuance of official documents and medical record copies. These services greatly contribute to reducing patient waiting times and enhancing communication efficiency with staff.
GC Genome announced on the 25th that a patent for 'AI-based detection methods for tumor-derived mutations from cell-free DNA and early cancer diagnosis methods using them' has officially been registered in Japan. The registered patent pertains to GC Genome's AI-based non-invasive minimal residual disease detection technology (G-MRD), which utilizes next-generation sequencing analysis methods to leverage both functional and sequential characteristics of cancer. It can accurately utilize mutations detected in low data volumes to enable early cancer diagnosis and is also applicable for detecting cancer recurrence, assessing treatment efficacy, and predicting patient prognosis. The company is currently developing a test that uses this technology to detect residual micro-cancer cells in patients who have been treated for breast and colorectal cancer to monitor recurrence.
GeoYoung, the leading pharmaceutical distribution company in South Korea, announced that sales of 'Zyrtec' (10 tablets) in March increased by 47.9% compared to the previous month. This data comes from an analysis of sales data collected from 459 pharmacies nationwide that have Point of Sale systems, conducted by the pharmaceutical research platform 'CareInsight', which showed Zyrtec's sales ranking rise from 53rd to 30th, a jump of 23 spots during the same period. Zyrtec is an over-the-counter medication that may help alleviate allergy symptoms triggered by pollen and other allergens.
DXVX announced on the 25th that it has launched six health supplements under its well-being nutrition brand 'Ofmom', which will be sold at major Daiso stores. The newly launched products include 'Stress, Rest', 'Skin Health Immune Tonic!!', 'Eye Health Aira-Light', 'Diet Holic', 'Memory Green-Light', and 'Vitamin C Plus Tonic!!'. The company stated that it conducts research and development of healthcare materials and products at its own microbiome research institute and produces quality products through stringent quality control at its subsidiary, Korea Biopharm (GMP) factory.
Dong-A Pharmaceutical announced on the 25th that its inner beauty brand Ailo has launched three new slimming product lines. The new products include Magburn Core Cut Ampoule, Dual Slim-cut, and Psyllium Husk Capsules, with a gummi variant set to launch next month.
Jeil Health Science announced that it will conduct a sampling promotion at CGV Yongsan I'Park Mall in collaboration with the multiplex cinema CGV from the 28th to the 11th of next month. Customers who purchase the 'CineMeal Set' during the promotional period will receive a bottle of carbonated liquid digestive aid 'Gas Myeongsu Liquid'. 'Gas Myeongsu Liquid' is exclusively supplied by Jeil Health Science under a sales agreement with SAMSUNG PHARM since the second half of last year.
Dr. Charles Wiener, International Medical Director of Johns Hopkins, a world-renowned medical institution in the United States, delivered a keynote speech on the 25th at the '3rd International Symposium on Patient-Centered In Vitro Fertilization (IVF) for Infertility', held at the CHA Bio Complex in Pangyo, Gyeonggi province. Dr. Wiener noted that he would work to create a platform that provides integrated medical services to patients worldwide based on CHA Hospital's medical technology, clinical research capabilities, and scientific and comprehensive data.
The Buchae Pyo Gasong Foundation and the Korean Dental Association jointly announced on the 25th the winners of the 14th Yun Gwang-yeol Dental Medical Volunteer Award as 'Seoul Special City Gangseo District Dental Association' and 'Lee Hwa-jun, Director of Jeonju Geun Il Dental Clinic, affiliated with the Jeonbuk Special Self-Governing Province Dental Association'. The Gangseo District Dental Association has been recognized for its significant contributions to free medical services for the disabled, which have been ongoing since September 2011, through the voluntary participation of its members, with around 2,500 disabled individuals treated over 14 years by 320 participating members. Joint winner Dr. Lee has been providing free dental treatment at the 'Jeonju Eunhwaschool for the Disabled' every Friday since 2000, and has been recognized for his contributions to raising the status of Korean dental practitioners through medical volunteer work in India, Nepal, Mongolia, and Cambodia.
Sugentech announced on the 25th that it has officially launched 'Surely Early Check Fast', a product that dramatically improves diagnostic speed. Unlike existing products, which typically confirm results within 3 to 5 minutes, Surely Early Check Fast applies rapid reading technology that accurately confirms pregnancy status in about a minute, minimizing user wait times. It also achieves high sensitivity, allowing for the rapid and accurate detection of the pregnancy hormone (hCG) even in the very early stages after ovulation. This is an achievement based on Sugentech's accumulated immunochemistry-based in vitro diagnostic technology and automated manufacturing facilities.
Neoimmunetech announced on the 25th that it will present research results demonstrating that NT-I7 (Efineptakin alfa) boosts lymphocyte counts and enhances anti-cancer effects in nonclinical models of head and neck squamous cell carcinoma (HNSCC) at the American Association for Cancer Research (AACR 2025) to be held in Chicago from the 25th to the 30th. This study was conducted in collaboration with the University of California, San Francisco (UCSF) and focused on analyzing the immunological synergy effects of NT-I7 when administered in combination with cisplatin, which is used as a standard treatment for HNSCC, and anti-PD-1 immune checkpoint inhibitors.
ImmuneOncia announced on the 25th that it will present the nonclinical research results of its anti-CD47 immune cancer drug IMC-002 at the American Association for Cancer Research (AACR 2025) to be held in Chicago from the 25th to the 30th. IMC-002 is an IgG4 monoclonal antibody that blocks the 'don't eat me' signal (CD47-SIRPα) allowing immune cells to engage in anticancer activity. Clinical phase 1b trials are currently underway for patients with solid tumors, and it is being developed as a macrophage-based immune checkpoint inhibitor.
Daewoong Pharmaceutical announced on the 25th that it has conducted a 'Special Health Checkup Day' in collaboration with the Gangneung Asan Hospital Health Medicine Center for 185 employees aged 40 and over, providing digital healthcare-based health checkups that include sarcopenia and fundus examinations. Daewoong Pharmaceutical supported digital devices for ophthalmic and sarcopenia screenings for the employees participating in this checkup. The eye health examination utilized the AI diagnostic assist solution 'WISKY', which can diagnose three major blindness diseases including diabetic retinopathy, age-related macular degeneration, and glaucoma simultaneously, as well as a fundus camera 'OPTiNA Genesis' that captures internal structures of the eye such as the retina, choroid, and optic nerve to diagnose and manage various ocular diseases.